Finoriq research workspace
Allogene Therapeutics, Inc. (ALLO) SEC Filings & Filing Highlights
Allogene Therapeutics, Inc. a clinical stage immuno-oncology company, develops and commercializes. Review ALLO SEC filings, filing highlights, and disclosure activity on Finoriq.
Company Snapshot
Allogene Therapeutics, Inc. a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer and autoimmune diseases. It develops a pipeline of multiple allogeneic CAR T cell product candidates utilizing protein engineering, gene editing, gene insertion, and advanced proprietary T cell manufacturing technologies. The company is also developing cemacabtagene ansegedleucel (cema-cel), an engineered allogeneic CAR T cell product candidate that targets CD19 for the treatment of large B-cell lymphoma (LBCL). In addition, it develops ALLO-316, an engineered allogeneic CAR T cell product candidate that targets CD70 to treat renal cell carcinoma (RCC); and ALLO-329, an engineered allogeneic CAR T cell product candidate that targets both CD19 and CD70 for the treatment of autoimmune diseases (AID), such as systemic lupus erythematosus (SLE), idiopathic inflammatory myopathies (IIM), and systemic sclerosis (SSc). The company was incorporated in 2017 and is headquartered in South San Francisco, California.
- Company
- Allogene Therapeutics, Inc. (ALLO)
- Ticker
- ALLO
- Market Cap
- $614.4M
- Latest Price
- $1.78
- Industry
- Biotech & Pharma
Allogene Therapeutics, Inc. (ALLO) Recent SEC Filing Highlights
Recent SEC filings, filing events, and disclosure highlights indexed for Allogene Therapeutics, Inc. (ALLO).
| Event | Form | Date |
|---|---|---|
| Allogene Therapeutics, Inc.: Corporate updateOn June 22, 2026, the Company filed a prospectus supplement (the "Prospectus Supplement") with the Securities and Exchange Commission relat... | 8-K8.01 | 2026-06-22 |
| On June 18, 2026, Allogene Therapeutics, Inc. held its 2026 Annual Meeting of Stockholders. At...On June 18, 2026, Allogene Therapeutics, Inc. (the "Company") held its 2026 Annual Meeting of Stockholders (the "Annual Meeting"). At the A... | 8-K5.07 | 2026-06-22 |
| On May 28, 2026, the Board of Directors (the “Board”) of Allogene Therapeutics, Inc. (the “Comp...On May 28, 2026, the Board of Directors (the “Board”) of Allogene Therapeutics, Inc. (the “Company”), upon the recommendation of its Nomina... | 8-K5.02 | 2026-05-28 |
| Allogene Therapeutics, Inc.: Earnings or resultsOn May 13, 2026, Allogene Therapeutics, Inc. (the “Company”) provided a corporate update and announced its financial results for the quarte... | 8-K2.02 | 2026-05-13 |
| Allogene Therapeutics, Inc.: Material agreementOn May 12, 2026, Allogene Therapeutics, Inc. (“Allogene”) entered into (i) a Termination Agreement (the “Termination Agreement”) with Overl... | 8-K1.01 | 2026-05-13 |
Live data loads in the app
This static page shell gives search engines reliable page context. Current tables, filings, charts, and market data continue to load from Finoriq APIs after the application starts.